Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Tuberous Sclerosis 1Pyloric Stenosis, Hypertrophic 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphangioleiomyomatosis 1HER2-positive Breast Cancer 1Colorectal Neoplasms 1Breast Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Bevacizumab 25Fluorouracil 23Leucovorin 22Cetuximab 22Oxaliplatin 19pembrolizumab 14Specimen Handling 10Irinotecan 10Nivolumab 8Magnetic Resonance Spectroscopy 8atezolizumab 6Biopsy 6fludarabine 5encorafenib 5Pemetrexed 5Panitumumab 5HMPL-013 5Gemcitabine 5Folfox protocol 5Cisplatin 5Carboplatin 5trifluridine tipiracil drug combination 4Standard of Care 4Immunoglobulin G 4Disulfides 4Cyclophosphamide 4regorafenib 3fludarabine phosphate 3dehydroftorafur 3binimetinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Genetic Testing × 30 days × Clear all
NCT05649072 2026-05-22

Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

M.D. Anderson Cancer Center

Phase NA Recruiting
1,000 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡